Lifespan Vision Ventures Leads Remedium Bio's Series A Financing

Lifespan Vision Ventures has led a $10 million Series A financing round for Remedium Bio, Inc., a biotechnology company focused on developing durable protein therapeutics. The initial closing of this financing was completed on August 10, 2026, with notable participation from Eli Lilly and Company and HKX Capital. As part of this investment, Harry Robb from Lifespan Vision Ventures will join Remedium's Board of Directors, indicating a strategic partnership aimed at advancing the company's innovative therapeutic platform.

Remedium Bio is at the forefront of biotechnology, developing a unique platform that utilizes adipocytes for the controlled and long-lasting expression of therapeutic proteins. This approach aims to provide patients with chronic diseases a more effective treatment option through minimally invasive subcutaneous administration. The funding from this Series A round will be instrumental in advancing Remedium's lead programs and preparing for first-in-human clinical studies, which are critical milestones in the development of new therapeutics.

The strategic rationale behind this investment aligns with the growing demand for innovative solutions in the treatment of chronic diseases. Traditional biologic therapies often require frequent dosing and can present challenges in patient adherence. Remedium's platform, which allows for multi-year therapeutic benefits and adjustable dosing, addresses these limitations and positions the company to potentially transform the treatment landscape for various chronic conditions, including those in the fields of endocrinology, immunology, neurology, and musculoskeletal diseases.

The participation of established players like Eli Lilly and HKX Capital underscores the confidence in Remedium's technology and its potential market impact. Eli Lilly, a leader in the pharmaceutical sector, has a vested interest in advancing novel therapeutic modalities that can enhance patient outcomes. This collaboration may also facilitate future partnerships and commercialization opportunities as Remedium progresses through clinical development.

In summary, this $10 million Series A financing not only provides essential capital for Remedium Bio but also highlights the increasing interest in biotechnology solutions that promise durable and effective treatments for chronic diseases. As the company advances its pipeline and prepares for clinical trials, the broader implications for the biotechnology sector may include a shift toward more innovative, long-lasting therapies that can improve patient quality of life while addressing significant unmet medical needs.